Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11235200 | 0.80 | TSHR (0.42) | TSHRTHPOMAPTTDP1EHMT2 | |
| SCHEMBL107282 | 0.73 | TSHR (0.39) | TSHRTHPOMAPTTDP1EHMT2 | |
| SCHEMBL2132212 | 0.73 | TSHR (0.45) | TSHRTHPOMAPTTDP1EHMT2 | |
| SCHEMBL15377006 | 0.71 | TSHR (0.33) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL26133478 | 0.71 | TSHR (0.50) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL21590125 | 0.71 | TSHR (0.55) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL31707345 | 0.71 | TSHR (0.50) | TSHRTHPOMAPTTDP1EHMT2 | |
| Cystamine SCHEMBL1700588 | 0.71 | TSHR (0.55) | TSHRTHPOMAPTTDP1EHMT2 | |
| SCHEMBL29037561 | 0.70 | TSHR (0.36) | TSHRTHPOMAPTTDP1EHMT2 | |
| SCHEMBL3319884 | 0.70 | ZDHHC20 (0.42) | TSHRTDP1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119818456-A | Preparation method of negatively charged melittin nanocapsules targeting tumor microenvironment | 北京化工大学 | 2025-04-15 | — | — | CN | disclosed |
| CN-116098868-B | Size-variable targeted drug-loaded micelle for treating cerebral arterial thrombosis and preparation method thereof | 西南交通大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-116098868-A | Size-variable targeted drug-loaded micelle for treating cerebral arterial thrombosis and preparation method thereof | 西南交通大学 | 2023-05-12 | — | — | CN | disclosed |
| US-6514535-B2 | For drug delivery | NOVEON IP HOLDINGS CORP. | 2003-02-04 | — | — | US | disclosed |
| US-20020068087-A1 | BIOADHESIVE HYDROGELS WITH FUNCTIONALIZED DEGRADABLE CROSSLINKS | NOVEON IP HOLDINGS CORP., FORMERLY KNOWN AS PMD HOLDINGS CORP. | 2002-06-06 | — | — | US | disclosed |
| EP-1178848-A1 | BIOADHESIVE HYDROGELS WITH FUNCTIONALIZED DEGRADABLE CROSSLINKS | Noveon IP Holdings Corp. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071180-A1 | BIOADHESIVE HYDROGELS WITH FUNCTIONALIZED DEGRADABLE CROSSLINKS | NOVEON IP HOLDINGS CORP. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068087-A1 | BIOADHESIVE HYDROGELS WITH FUNCTIONALIZED DEGRADABLE CROSSLINKS | CD44, EPCAM, BSG | TSHR 1788/4885THPO 3504/4885MAPT 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.